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1,2,3-Triazole is a well known important heterocycle both in
synthetic as well as medicinal chemistry due to its simple
synthesis via click chemistry approach and a wide range of
biological activities. Simple copper catalyzed 1,3-dipolar
cycloadditions of substituted azides and alkynes afford
regioselective 1,4-disubstitued 1,2,3-triazoles with high yields.
1,2,3-Triazole with high dipole moment, considerable stability
and capability for hydrogen bonding make it a favorable bin-
der of biomolecular targets. 1,2,3-Triazole derivatives werereported to exhibit various biological activities such as antidia-
betic [1], antitubercular [2,3], anti-inﬂammatory [4], antifungal
[5–7], antiviral [8,9] and antibacterial [10,11]. Several drugs like
carboxyamidotriazole, cefatrizine, and tazobactam bear 1,2,3-
triazole in their structure. Moreover, Ruﬁnamide, the amide of
1-(2,6-diﬂuorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid is an
antiepileptic drug, which is used in the treatment of partial sei-
zures and drop attacks associated with the Lennox–Gastaut
syndrome [12].
Piperazines are considered as a useful and effective scaffold
in drug design as they exhibit awide range of biological activities
such as FAAH andMAGL inhibitors [13], human histamine H4
antagonist [14], and cannabinoid ligands [15].Recently, piperazine
bearing 1,2,3-triaozles are reported as potential anticancer,
antiproliferative agents [16,17]. On the other hand, 1,3,4-
oxadiazole is also a signiﬁcant heterocycle that exhibit activities
such as antimicrobial [18–23], anti-inﬂammatory, analgesic
[24,25], antitubercular [26–28], anticonvulsant [29], antidiabetic
[30] and anticancer [31]. In view of these ﬁndings and in con-
tinuation of our earlier attempts for the design and synthesis
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and anti-inﬂammatory agents [32,33], we report herein the
synthesis and antimicrobial evaluation of a series of piperazine
carboxamide and 1,3,4-oxadiazole derivatives of 1-(2,6-diﬂuo-
robenzyl)-1H-1,2,3-triazole-4-carboxylic acid as possible
antimicrobial agents.
2. Experimental
2.1. Materials and measurements
All chemicals used were of laboratory grade and used without
further puriﬁcation. Melting points of compounds were deter-
mined in open capillary tubes in a silicon oil bath using a
Veego melting point apparatus and are uncorrected. Purity
of compounds was monitored by TLC on silica F254 coated
aluminum plates (Merck) as adsorbent and U.V. light and
iodine as visualizing agents. 1H and 13C NMR spectra were
recorded on Varian mercury TH-300 operating at 300 MHz
(1H NMR) and 75 MHz (13C NMR) using CDCl3 and
DMSO-d6 as solvents and TMS as an internal standard
(Chemical shift in ppm). The High Resolution Mass Spectra
were recorded on Waters QT micro-mass analyzer.2.2. Preparation methods
2.2.1. Synthesis of 1-(2,6-diﬂuorobenzyl)-1H-1,2,3-triazole-4-
carboxylic acid (3)
Yield 85%, mp: 165–168 C. 1H NMR (300 MHz, DMSO-d6):
d 5.72 (s, 2H, Ar-CH2), 7.14–7.21 (m, 2H, Ar-H), 7.49–7.54 (m,
1H, Ar-H), 8.74 (s, 1H, triazole-H), 13.40 (s, 1H, –COOH).
2.2.2. General procedure for the synthesis of (1-(2,6-
diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-substituted piperazin-
1-yl)methanone (4a–k)
To a cooled solution of 1-(2,6-diﬂuorobenzyl)-1H-1,2,3-tria-
zole-4-carboxylic acid (3) (1.0 mol) in DMF (10 mL) was
added HOBt (1.1 mol) followed by corresponding piperazine
(1.1 mol) TEA (2.1 mol) and EDCÆHCl (1.1 mol). The reaction
mixture was left overnight with stirring. The mixture was then
poured onto crushed ice; the product was ﬁltered and washed
with water. The crude products (4a–k) were puriﬁed by column
chromatography using hexane:EtOAc (9:1) as eluent.2.2.2.1. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-Bocpi
perazin-1-yl)methanone (4a). Yield 95%, mp: 168–169 C. 1H
NMR (300 MHz, CDCl3): d 1.47(s, 9H, –C(CH3)3), 3.51 (s,
4H, piperazine-H), 3.72 (t, 2H, piperazine-H), 4.27 (t, 2H,
piperazine-H), 5.65 (s, 2H, Ar-CH2), 6.99 (t, 2H, Ar-H),
7.35-7.45 (m, 1H, Ar-H), 8.11 (s, 1H, triazole-H); 13C NMR
(75 MHz, CDCl3): d 28.3, 41.5, 42.5, 46.4, 80.2, 110.0, 111.7,
112.0, 128.3, 131.8, 144.4, 154.5, 159.7, 162.9.
2.2.2.2. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-(2-met
hoxyphenyl)piperazin-1-yl) methanone (4b). Yield 89%, mp:
121–122 C. 1H NMR (300 MHz, CDCl3): d 3.11 (s, 4H, piper-
azine-H), 3.86 (s, 3H, –OCH3), 3.93 (s, 2H, piperazine-H), 4.45
(s, 2H, piperazine-H), 5.62 (s, 2H, Ar-CH2), 6.90–7.05 (m, 6H,
Ar-H), 7.37–7.43 (m, 1H, Ar-H), 8.15 (s, 1H, triazole-H); 13C
NMR (75 MHz, CDCl3): d 41.4, 42.8, 46.8, 50.7, 51.2, 55.4,110.1, 111.2, 111.7, 112.0, 118.4, 121.0, 123.4, 128.2, 131.7,
140.7, 144.6, 152.2, 159.6, 163.0.
2.2.2.3. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-(4-ch
lorophenyl)piperazin-1-yl)methanone (4c). Yield 90%, mp:
149–151 C. 1H NMR (300 MHz, CDCl3): d 3.20 (t, 4H, piper-
azine-H), 3.90 (t, 2H, piperazine-H), 4.45 (t, 2H, piperazine-
H), 5.65 (s, 2H, Ar-CH2), 6.84 (d, 2H, Ar-H), 6.98 (t, 2H,
Ar-H), 7.21 (d, 2H, Ar-H), 7.34-7.43 (m, 1H, Ar-H), 8.11 (s,
1H, triazole-H); LC–MS [M+H]+: 418.1179.
2.2.2.4. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-p-toly
lpiperazin-1-yl)methanone (4d). Yield 95%, mp: 147–149 C.
1H NMR (300 MHz, CDCl3): d 2.27 (s, 3H, –CH3), 3.20 (s,
4H, piperazine-H), 3.92 (s, 2H, piperazine-H), 4.46 (s, 2H,
piperazine-H), 5.66 (s, 2H, Ar-CH2), 6.88 (s, 2H, Ar-H), 6.98
(t, 2H, Ar-H), 7.09 (d, 2H, Ar-H), 7.34–7.41 (m, 1H, Ar-H),
8.12 (s, 1H, triazole-H).
2.2.2.5. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-(4-nit
rophenyl)piperazin-1-yl)methanone (4e). Yield 85%, mp:
170–172 C. 1H NMR (300 MHz, CDCl3): d 3.52 (t, 4H, piper-
azine-H), 3.92 (t, 2H, piperazine-H), 4.51 (t, 2H, piperazine-
H), 5.66 (s, 2H, Ar-CH2), 6.83 (d, 2H, Ar-H), 6.99 (t, 2H,
Ar-H), 7.34–7.44 (m, 1H, Ar-H), 8.14 (s, 1H, triazole-H),
8.15 (d, 2H, Ar-H); LC–MS [M+H]+: 429.1465.
2.2.2.6. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)[4-(2-(tri-
ﬂuoromethyl)phenyl)piperazin-1-yl] methanone (4f).Yield 89%,
mp: 155–158 C. 1H NMR (300 MHz, CDCl3): d 3.29 (t, 4H,
piperazine-H), 3.92 (t, 2H, piperazine-H), 4.48 (t, 2H, piper-
azine-H), 5.65 (s, 2H, Ar-CH2), 6.98 (t, 2H, Ar-H), 7.06–7.12
(m, 3H, Ar-H), 7.33–7.41 (m, 2H, Ar-H), 8.12 (s, 1H, triazole-
H); 13C NMR (75 MHz, CDCl3): d 41.5, 42.4, 46.2, 48.9, 49.4,
110.1, 111.7, 112.0, 112.6, 116.5, 119.2, 122.3, 125.3, 128.3,
129.6, 131.7, 131.7, 144.4, 151.1, 159.6, 163.0; LC–MS
[M+H]+: 452.1576.
2.2.2.7. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-(3,4-di
chlorophenyl)piperazin-1-yl) methanone (4g). Yield 92%, mp:
145–147 C. 1H NMR (300 MHz, CDCl3): d 3.22 (t, 4H, piper-
azine-H), 3.89 (s, 2H, piperazine-H), 4.46 (s, 2H, piperazine-H),
5.65 (s, 2H, Ar-CH2), 6.75 (dd, 1H, Ar-H), 6.96–7.01 (m, 2H,
Ar-H), 7.27–7.30 (m, 2H, Ar-H), 7.36–7.41 (m, 1H, Ar-H), 8.12
(s, 1H, triazole-H); LC–MS [M+H]+: 452.0840.
2.2.2.8. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-benzy
lpiperazin-1-yl)methanone (4h). Yield 87%, mp: 140–142 C.
1H NMR (300 MHz, CDCl3): d 2.47–2.52 (m, 4H, piper-
azine-H), 3.52 (s, 2H, Ar-CH2), 3.75 (t, 2H, piperazine-H),
4.27 (t, 2H, piperazine-H), 5.63 (s, 2H, Ar-CH2), 6.97 (t, 2H,
Ar-H), 7.28-7.40 (m, 7H, Ar-H), 8.07 (s, 1H, triazole-H).
2.2.2.9. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-(4-ch
lorobenzyl)piperazin-1-yl)methanone (4i). Yield 91%, mp:
165–168 C. 1H NMR (300 MHz, CDCl3): d 2.43 (t, 4H, piper-
azine-H), 3.74 (s, 2H, piperazine-H), 4.23 (s, 2H, Ar-CH2),
4.25 (s, 2H, piperazine-H), 5.61 (s, 2H, Ar-CH2), 6.95 (t, 2H,
Ar-H), 7.16–7.41 (m, 5H, Ar-H), 8.05 (s, 1H, triazole-H); 13C
NMR (75 MHz, CDCl3): d 41.4, 42.7, 46.7, 51.5, 52.3, 75.1,
110.0, 111.8, 127.3, 127.8, 128.0, 128.7, 129.1, 131.7, 132.7,
140.7, 141.5, 144.6, 159.5, 163.0.
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(4-chlorophenyl)methyl)piperazin-1-yl]methanone (4j). Yield
84%, mp: 170–172 C. 1H NMR (300 MHz, CDCl3): d 2.41
(s, 4H, piperazine-H), 3.75 (s, 2H, piperazine-H), 4.23 (s, 3H,
piperazine-H,-CH), 5.61 (s, 2H, Ar-CH2), 6.96 (t, 2H, Ar-H),
7.19–7.39 (m, 9H, Ar-H), 8.05 (s, 1H, triazole-H).
2.2.2.11. (1-(2,6-Diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)(4-(pyr
idin-2-yl)piperazin-1-yl)methanone (4k). Yield 86%, mp:
80–82 C. 1H NMR (300 MHz, CDCl3): d 3.64 (s, 4H, piper-
azine-H), 3.88 (t, 2H, piperazine-H), 4.42 (t, 2H, piperazine-
H), 5.66 (s, 2H, Ar-CH2), 6.64–6.66 (m, 2H, Ar-H), 6.99 (t,
2H, Ar-H), 7.34–7.42 (m, 1H, Ar-H), 7.47–7.53 (m, 1H, Ar-
H), 8.15 (s, 1H, triazole-H), 8.19–8.21 (m, 1H, Ar-H); 13C
NMR (75 MHz, CDCl3): d 41.4, 42.3, 44.8, 45.7, 46.1, 107.0,
110.0, 111.6, 111.9, 113.6, 114.1, 128.2, 130.2, 130.9, 131.6,
132.6, 137.5, 144.4, 147.8, 159.0, 159.7, 162.9; LC–MS
[M+H]+: 385.1512.
2.2.3. Procedure for the synthesis of methyl-1-(2,6-diﬂuoroben
zyl)-1H-1,2,3-triazole-4-carboxylate (5)
To a solution of acid 3 in dry MeOH, a catalytic amount of
conc. H2SO4 was added and the mixture was then reﬂuxed
for 7–8 h. After the reaction was complete, excess solvent
was removed under vacuum and crushed ice was added to
the resulting solid. The solid was ﬁltered and washed with
water to obtain the product in 89% yield. mp: 132–135 C.
1H NMR (300 MHz, CDCl3): d 3.93 (s, 3H, –OCH3), 5.69 (s,
2H, Ar-CH2), 7.00 (t, 2H, Ar-H), 7.36–7.46 (m, 1H, Ar-H),
8.11 (s, 1H, triazole-H).
2.2.4. Procedure for the synthesis of 1-(2,6-diﬂuorobenzyl)-1H-
1,2,3-triazole-4-carbohydrazide (6)
The mixture of methyl ester 5 and hydrazine hydrate in ethanol
was reﬂuxed for 6 h on a water bath. After the reaction was
complete, the reaction mixture was cooled. The solid thus
obtained was ﬁltered and washed with water. Yield 85%,
mp: 229–231 C. 1H NMR (300 MHz, DMSO-d6): d 4.45 (s,
2H, –NH2), 5.72 (s, 2H, Ar-CH2), 7.20 (t, 2H, Ar-H), 7.48–
7.56 (m, 1H, Ar-H), 8.57 (s, 1H, triazole-H), 9.71 (s, 1H, –
NH).
2.2.5. General procedure for the synthesis of 1-(2,6-diﬂuoroben
zyl)-4-(5-(substitutedphenyl)-1,3,4-oxadiazol-2-yl)-1H-1,2,3-tr
iazoles (7a–g)
The mixture of 1-(2,6-diﬂuorobenzyl)-1H-1,2,3-triazole-4-
carbohydrazide 6 and corresponding substituted benzoic acid
in POCl3 was reﬂuxed for 8 h. The reaction mixture was then
cooled and poured onto the crushed ice. The solid separated
was ﬁltered, washed with water. The crude products (7a–g)
were puriﬁed by column chromatography using hexane:
EtOAc (8:2) as eluent.
2.2.5.1. 1-(2,6-Diﬂuorobenzyl)-4-(5-phenyl-1,3,4-oxadiazol-2-
yl)-1H-1,2,3-triazole (7a). Yield 79%, mp: 165–166 C. 1H
NMR (300 MHz, CDCl3): d 5.77 (s, 2H, Ar-CH2), 7.03 (t,
2H, Ar-H), 7.38–7.46 (m, 1H, Ar-H), 7.49–7.57 (m, 3H, Ar-
H), 8.17–8.20 (dd, 2H, Ar-H), 8.32 (s, 1H, triazole-H).
2.2.5.2. 1-(2,6-Diﬂuorobenzyl)-4-(5-(2-methylphenyl)-1,3,4-oxa
diazol-2-yl)-1H-1,2,3-triazole (7b). Yield 84%, mp: 181-184 C.1H NMR (300 MHz, CDCl3): d 2.74 (s, 3H, -CH3), 5.75 (s, 2H,
Ar-CH2), 7.00 (t, 2H, Ar-H), 7.30-7.43 (m, 4H, Ar-H), 8.06 (d,
1H, Ar-H), 8.30 (s, 1H, triazole-H); 13C NMR (75 MHz,
CDCl3): d 22.0, 41.8, 109.9, 111.9, 122.5, 124.4, 126.1, 129.2,
131.3, 131.7, 131.9, 134.2, 138.6, 157.5, 159.6, 162.9, 164.9.
2.2.5.3. 1-(2,6-Diﬂuorobenzyl)-4-(5-(3-chlorophenyl)-1,3,4-oxad
iazol-2-yl)-1H-1,2,3-triazole (7c). Yield 75%, mp: 190–191 C.
1H NMR (300 MHz, DMSO-d6): d 5.82 (s, 2H, Ar-CH2), 7.21
(t, 2H, Ar-H), 7.49–7.57 (m, 1H, Ar-H), 7.63–7.74 (m, 2H, Ar-
H), 8.03 (s, 1H, Ar-H), 8.06 (d, 1H, Ar-H), 9.15 (s, 1H, triazole-
H); 13C NMR (75 MHz, DMSO-d6): d 42.0, 110.0, 111.7, 124.9,
125.3, 126.0, 126.8, 131.4, 131.8, 132.0, 132.4, 133.9, 158.0,
159.1, 162.5; LC–MS [M+H]+: 374.0573.
2.2.5.4. 1-(2,6-Diﬂuorobenzyl)-4-(5-(4-chlorophenyl)-1,3,4-oxad
iazol-2-yl)-1H-1,2,3-triazole (7d). Yield 78%, mp: >225 C. 1H
NMR(300 MHz,DMSO-d6): d 5.83 (s, 2H,Ar-CH2), 7.22 (t, 2H,
Ar-H), 7.52-7.58 (m, 1H, Ar-H), 7.71 (d, J= 8.7 Hz, 2H, Ar-H),
8.09 (d, J= 8.7 Hz, 2H, Ar-H), 9.14 (s, 1H, triazole-H).
2.2.5.5. 1-(2,6-Diﬂuorobenzyl)-4-(5-(4-ﬂuorophenyl)-1,3,4-oxa
diazol-2-yl)-1H-1,2,3-triazole (7e). Yield 84%, mp: 184–
185 C. 1H NMR (300 MHz, CDCl3): d 5.77 (s, 2H, Ar-
CH2), 7.03 (t, 2H, Ar-H), 7.21 (d, 2H, Ar-H), 7.41–7.46 (m,
1H, Ar-H), 8.17–8.21 (m, 2H, Ar-H), 8.32 (s, 1H, triazole-H).
2.2.5.6. 1-(2,6-Diﬂuorobenzyl)-4-(5-(2,4-dichlorophenyl)-1,3,4
-oxadiazol-2-yl)-1H-1,2,3-triazole (7f). Yield 77%, mp: 190–
191 C. 1H NMR (300 MHz, CDCl3): d 5.77 (s, 2H, Ar-
CH2), 7.03 (t, 2H, Ar-H), 7.38–7.45 (m, 3H, Ar-H), 7.60 (d,
1H, Ar-H), 8.04 (d, 1H, Ar-H), 8.34 (s, 1H, triazole-H); LC–
MS [M+H]+: 408.0205.
2.2.5.7. 1-(2,6-Diﬂuorobenzyl)-4-(5-(3,4-dimethoxyphenyl)-
1,3,4-oxadiazol-2-yl)-1H-1,2,3-triazole (7g). Yield 74%, mp:
201–204 C. 1H NMR (300 MHz, CDCl3): d 3.97 (s, 3H, –
OCH3), 3.99 (s, 3H, –OCH3), 5.77 (s, 2H, Ar-CH2), 6.97–
7.06 (m, 3H, Ar-H), 7.38–7.46 (m, 1H, Ar-H), 7.66 (d,
J= 1.9 Hz, 1H, Ar-H), 7.77 (dd, J1 = 1.9 Hz, J2 = 8.5 Hz,
1H, Ar-H), 8.32 (s, 1H, triazole-H); LC–MS [M+H]+:
400.1136.
2.2.6. Procedure for the synthesis of 5-(1-(2,6-diﬂuorobenzyl)-
1H-1,2,3-triazol-4-yl)-1,3,4-oxadia-zole-2-thiol (8)
To a solution of carbohydrazide 6 (1.0 mol) in ethanol, an
aqueous solution of potassium hydroxide (3.0 mol) was added.
To this solution carbon disulﬁde (1.5 mol) was added and the
resulting solution was reﬂuxed in a water bath for 6 h. The
reaction mass was cooled, acidiﬁed with acetic acid. The solid
obtained was ﬁltered, washed with water and dried to afford
the target compound in 81% yield. mp: 203–205 C. 1H
NMR (DMSO-d6): d 5.79 (s, 2H, Ar-CH2), 7.21 (t, 2H, Ar-
H), 7.49–7.59 (m, 1H, Ar-H), 9.05 (s, 1H, triazole-H), 14.82
(bs, 1H, –SH); LC–MS [M+H]+: 296.0354.
2.2.7. General procedure for the synthesis of 1-(2,6-
diﬂuorobenzyl)-4-(5-(alkylthio)-1,3,4-oxadiazol-2-yl)-1H-
1,2,3-triazole (9a–e)
To a solution of compound 8 (1.0 mol) suspended in DMF,
alkyl halide (1.2 mol) and a catalytic amount of triethylamine
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bath at 50 C for 3–4 h. After the reaction was complete as
monitored on TLC, the mixture was cooled and poured onto
crushed ice. The solid thus obtained was ﬁltered, washed with
water. The crude products (9a–e) were puriﬁed by column
chromatography using hexane-ethyl acetate (8:2) as eluant.
2.2.7.1. 1-(2,6-Diﬂuorobenzyl)-4-(5-(ethylthio)-1,3,4-oxadiazo
l-2-yl)-1H-1,2,3-triazole (9a). Yield 90%, mp: 102–104 C. 1H
NMR (300 MHz, CDCl3): d 1.49 (t, 3H, –CH3), 3.28–3.35 (q,
2H, -SCH2), 5.75 (s, 2H, Ar-CH2), 7.01 (t, 2H, Ar-H), 7.38–
7.48 (m, 1H, Ar-H), 8.24 (s, 1H, triazole-H); 13C NMR
(75 MHz, CDCl3): d 14.5, 26.9, 41.8, 109.8, 111.9, 124.1,
131.9, 133.8, 158.8, 159.5, 162.9, 164.7; LC–MS [M+H]+:
324.0704.
2.2.7.2. 1-(2,6-Diﬂuorobenzyl)-4-(5-(isopropylthio)-1,3,4-oxad
iazol-2-yl)-1H-1,2,3-triazole (9b). Yield: 92%, mp: 150–152
C. 1H NMR (300 MHz, CDCl3): d 1.49 (d, 6H, 2 · –CH3),
3.91–4.00 (m, 1H, -CH), 5.73 (s, 2H, Ar-CH2), 7.00 (t, 2H,
Ar-H), 7.36–7.46 (m, 1H, Ar-H), 8.22 (s, 1H, triazole-H); 13C
NMR (75 MHz, CDCl3): d 23.2, 39.0, 41.8, 109.8, 111.9,124.1, 131.9, 133.9, 158.8, 159.6, 162.9, 164.4; LC–MS
[M+H]+: 338.0885.
2.2.7.3. 1-(2,6-Diﬂuorobenzyl)-4-(5-(butylthio)-1,3,4-oxadiazo
l-2-yl)-1H-1,2,3-triazole (9c). Yield 89%, mp: 66–67 C. 1H
NMR (300 MHz, CDCl3): d 0.95 (t, 3H, –CH3), 1.42–1.55
(m, 2H,-CH2CH3), 1.75–1.85 (m, 2H, –CH2), 3.27–3.32 (t,
2H, –SCH2), 5.73 (s, 2H, Ar-CH2), 7.01 (t, 2H, Ar-H), 7.37–
7.47 (m, 1H, Ar-H), 8.22 (s, 1H, triazole-H).
2.2.7.4. 1-(2,6-Diﬂuorobenzyl)-4-(5-(isopentylthio)-1,3,4-oxad
iazol-2-yl)-1H-1,2,3-triazole (9d). Yield 85%, mp: 154–
156 C. 1H NMR (300 MHz, CDCl3): d 0.86 (d, 6H, 2 · –
CH3), 1.40–1.48 (m, 1H, -CH), 1.57–1.68 (m, 2H, –CH2),
2.77 (t, 2H, –SCH2), 5.73 (s, 2H, Ar-CH2), 6.99 (t, 2H, Ar-
H), 7.35–7.45 (m, 1H, Ar-H), 8.12 (s, 1H, triazole-H).
2.2.7.5. 1-(2,6-Diﬂuorobenzyl)-4-(5-(benzylthio)-1,3,4-oxadia-
zol-2-yl)-1H-1,2,3-triazole (9e). Yield 91%, mp: 159–161 C.
1H NMR (300 MHz, CDCl3): d 4.50 (s, 2H, –SCH2), 5.71 (s,
2H, Ar-CH2), 6.92–7.01 (m, 3H, Ar-H), 7.37–7.40 (m, 5H,
Ar-H), 8.20 (s, 1H, triazole-H); LC–MS [M+H]+: 386.0885.
Table 1 Antimicrobial activity of the title compounds; diameter of inhibition zone in mm.
Compd Microorganisms*
A B C D E F G H I J K
4a – – 17.66 19.52 18.09 18.24 18.69 – 16.71 16.66 18.21
4b – 17.33 19.01 18.89 18.00 16.50 17.75 18.08 – 17.68 19.03
4c 17.82 19.23 18.23 18.64 19.26 18.24 19.04 17.56 – 18.22 19.01
4d 18.86 17.69 – – – – – – 18.71 16.96 17.64
4e 18.82 19.00 16.94 18.72 19.35 18.92 17.86 19.87 18.87 18.00 19.03
4f – – 17.24 – 18.96 18.21 19.01 18.77 – – –
4g 18.71 18.72 17.92 20.11 19.23 17.99 18.09 20.22 18.96 19.21 18.87
4h – 17.66 – 19.97 20.01 – 17.09 19.83 16.97 20.07 17.56
4i 17.98 – 17.39 20.07 18.07 18.22 15.69 20.09 – 18.66 19.08
4j – 19.04 18.77 – – – – 18.87 16.55 – –
4k 19.00 – 15.69 – 20.34 20.01 19.04 – – 19.24 16.54
7a 19.02 – 18.22 17.83 19.00 17.82 17.23 – 18.88 16.64 17.01
7b 17.98 16.96 18.27 16.86 – 18.84 17.52 15.69 17.66 15.96 19.00
7c 19.11 18.71 – – 17.84 – – 18.00 18.08 19.23 18.87
7d 18.92 – 17.62 19.06 18.88 17.96 19.01 18.09 17.86 19.22 17.62
7e 18.74 19.07 – – 18.24 – 17.55 16.66 – 18.21 17.86
7f 16.66 18.71 – 19.00 17.52 – 18.27 – 19.24 17.28 16.90
7g – 18.00 17.92 17.91 – 19.54 – – 18.77 19.08 17.81
9a 16.69 – 18.36 18.00 – 17.66 16.96 17.23 18.06 17.58 16.46
9b 17.66 – 17.02 – – – – 16.86 17.86 18.01 18.23
9c 18.03 18.22 – 17.65 17.76 16.91 17.53 16.88 15.62 19.03 –
9d – 19.06 18.22 16.64 18.82 17.22 18.07 – – – 17.84
9e – 17.42 18.21 – 18.91 18.62 – – – – 16.69
Chloramphenicol 22.26 22.64 21.26 24.18 23.56 22.67 22.50 NA NA NA NA
Nystatin NA NA NA NA NA NA NA 23.09 20.12 23.11 22.01
* (A) E. coli; (B) P. aeruginosa; (C) B. subtilis; (D) S. pyogenes; (E) K. pneumonia; (F) S. aureus; (G) K. terrigena; (H) C. albicans; (I) T. viride;
(J) A. ﬂavus; (K) A. brasiliensis.
 (–) Inactive.
 (NA) Not Applicable.
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3.1. Chemistry
Methodologies adopted for the synthesis of the title compounds
4a–k, 7a–g and 9a–e are shown in Schemes 1 and 2, respectively.
Starting from commercially available 2,6-diﬂuorobenzyl
bromide 1, the corresponding 1-(2,6-diﬂuorobenzyl)-1H-1,2,3-
triazole-4-carboxylic acid 3was obtained by reported procedure
[34]. 1H NMR data were in accordance with the expected struc-
ture. Emergence of signals at d 8.74 and d 12.20 for triazole ring
proton and acid proton respectively conﬁrmed the formation of
acid 3. The 1H NMR analysis of corresponding carboxamide
derivatives 4a–k revealed three sets of protons in the aliphatic
region (between d 3–5) for piperazine. Further, esteriﬁcation
of 3 was achieved by reﬂuxing the acid in dry MeOH, and a cat-
alytic amount of conc. H2SO4 for 7–8 h. The formation of
methyl ester 5was conﬁrmed by 1HNMR in which the methoxy
protons appeared at d 3.93. Thereafter, the Methyl-1-(2,6-di-
ﬂuorobenzyl)-1H-1,2,3-triazole-4-carboxylate 5 was converted
to its carbohydrazide derivative 6 by reﬂuxing it with hydrazine
hydrate in ethanol for 6 h. 1H NMR of 1-(2,6-diﬂuorobenzyl)-
1H-1,2,3-triazole-4-carbohydrazide 6 showed signals at d 4.45
for –NH2 protons and at d 9.71 for –NH proton.
Synthesis of the title compounds 1-(2,6-diﬂuorobenzyl)-4-(5-
(substitutedphenyl)-1,3,4-oxadiazol-2-yl)-1H-1,2,3-triazoles
7a–g was accomplished by reﬂuxing carbohydrazide 6 with
different substituted benzoic acids in POCl3 for 8 h.5-(1-(2,6-diﬂuorobenzyl)-1H-1,2,3-triazol-4-yl)-1,3,4-oxadia-
zole-2-thiol 8 was obtained by reﬂuxing carbohydrazide 6 with
carbon disulﬁde and potassium hydroxide in ethanol. Thiol 8
was alkylated using different alkyl halides in DMF containing
a catalytic amount of triethylamine to obtain ﬁnal compounds
1-(2,6-diﬂuorobenzyl)-4-(5-(alkylthio)-1,3,4-oxadiazol-2-yl)-
1H-1,2,3-triazoles 9a–e.
3.2. Antimicrobial activity
The newly synthesized compounds were evaluated for their anti-
bacterial activity against seven different bacterial strains,
Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis,
Streptococcus pyogenes, Klebsiella pneumonia, Streptococcus
aureus, and Klebsiella terrigena. Four fungal strains, Candida
albicans, Trichoderma viride, Aspergillus ﬂavus, and
Aspergillus brasiliensis were used for the antifungal screening
of the compounds. Agar disc diffusion assay method was used
for testing. Discs with 6 mm diameter were used for sample
loading. The test compounds with concentration 100 lg/mL
were prepared using DMSO. Chloramphenicol and Nystatin
were used as standard antibacterial and antifungal drugs for
the comparison of activities. Inhibition zone in mm of diameter
andminimum inhibitory concentrations (MIC) in lg/mL for the
tested compounds are summarized in Tables 1 and 2 respec-
tively. The investigation of antibacterial and antifungal screen-
ing results revealed that most of the test compounds exhibited
moderate to good activities as compared to the standard drugs.
Table 2 Antimicrobial activity of the title compounds; minimum inhibitory concentrations (MIC) in lg/mL.
Compd Microorganisms*
A B C D E F G H I J K
4a – – 70 60 80 80 60 – 80 100 60
4b – 70 50 70 80 90 70 60 – 90 50
4c 80 50 60 70 70 80 50 70 – 80 50
4d 70 70 – – – – – – 70 100 70
4e 70 50 80 70 70 70 70 50 70 80 50
4f – – 70 – 80 80 50 60 – – –
4g 70 60 70 60 70 90 60 50 70 70 60
4h – 70 – 70 60 – 70 50 80 60 70
4i 80 – 70 60 80 80 90 50 – 80 50
4j – 50 60 – – – – 60 80 – –
4k 60 – 90 – 60 60 50 – – 70 70
7a 60 – 60 80 60 80 70 – 80 80 70
7b 80 80 60 90 – 70 70 80 90 90 50
7c 60 60 – – 80 – – 60 80 60 60
7d 70 – 80 60 70 70 50 60 90 60 70
7e 70 50 – – 70 – 70 70 – 70 70
7f 90 60 – 60 80 – 60 – 70 80 70
7g – 60 70 80 – 60 – – 80 60 70
9a 80 – 60 70 – 70 70 70 70 80 80
9b 80 – 70 – – – – 80 80 70 60
9c 70 60 – 80 70 80 60 60 90 60 –
9d – 50 60 90 70 70 50 – – – 70
9e – 70 60 – 60 60 – – – – 80
Chloramphenicol 50 40 40 50 50 50 40 NA NA NA NA
Nystatin NA NA NA NA NA NA NA 40 60 50 40
* (A) E. coli; (B) P. aeruginosa; (C) B. subtilis; (D) S. pyogenes; (E) K. pneumonia; (F) S. aureus; (G) K. terrigena; (H) C. albicans; (I) T. viride;
(J) A. ﬂavus; (K) A. brasiliensis.
 (–) Inactive.
 (NA) Not Applicable.
Evaluation of 1,4-disubstituted 1,2,3-triazole derivatives as antimicrobial agents 157Compounds 4e and 4g were active against all the tested spe-
cies. Compound 4c was active against all the species except T.
viride. Compounds 4b, 4c, 4e, and 4i were signiﬁcantly effective
against A. brasiliensis. Compounds 4e, 4g, 4h, and 4i were sig-
niﬁcantly active against C. albicans. Compound 4k was effec-
tive against E. coli, K. pneumonia, S. aureus, K. terrigena and
A. ﬂavus. In fact, it was the most active compound against
S. aureus. Compounds 4c, 4e, and 4j showed signiﬁcant inhibi-
tion of bacteria P. aeruginosa. For E. coli, 4k exhibited good
activity. The most active compound against the B. subtilis
was 4b. Compound 4g and 4i were active against S. pyogenes.
The enhanced activities can be attributed to the presence of
biologically active piperazine ring bearing different aryl sub-
stitutions at the nitrogen. In case of the 4-(5-(substituted
aryl)-1,3,4-oxadiazol-2-yl)1H-1,2,3-triazole derivatives, almost
all the title compounds showed moderate to good activities.
Compound 7b was found to be most active against all the
tested pathogens except K. pneumonia. Compound 7d was sig-
niﬁcantly active against all the species except P. aeruginosa.
Compound 7f was found to be most active and comparable
with the standard drug against T. viride. Compound 7e was
good against bacteria P. aeruginosa. Against E. coli, 7a, and
7c exhibited good activity. It was noteworthy that almost all
the compounds having halo-substituted phenyl rings at the 5-
position of the 1,3,4-oxadiazole ring exhibit signiﬁcant activity
against the tested microorganisms. When the aryl substitutions
at the 5-position of the 1,3,4-oxadiazole ring were replaced by
thioalkyl substitutions, compound 9a, 9b and 9c bearing ethyl,iso-propyl and n-butyl substitutions respectively, retained the
activities. Although compound 9d and 9e were least active
against the tested fungi, they retained activities against the
bacterial strains. The overall results indicate that most of the
synthesized compounds showed moderate to good activity
against different tested microorganisms.
4. Conclusions
The present work reports the synthesis and in vitro biological
evaluation of a new series of 1,4-disubstituted 1H-1,2,3-tria-
zole derivatives having carboxamide and 1,3,4-oxadiazolyl
substitutions at the 4-position. The antimicrobial study
revealed that 1,2,3-triazole clubbed with 5-substituted 1,3,4-
oxadiazoles and N-substituted piperazines showed good activi-
ties against pathogenic strains. The presence of a piperazine
ring, halo-substituted phenyl rings in the structure, enhanced
the activities of the synthesized compounds. Further modi-
ﬁcations of these new molecules are warranted which could
provide more interesting results and new lead molecules for
further studies.
Acknowledgements
Authors are thankful to the BCUD, University of Pune and
CSIR, New Delhi, India for the ﬁnancial support. Authors
would like to acknowledge the SAIF, Punjab University,
Chandigarh, India for the Mass analysis.
158 R.P. Jadhav et al.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jscs.2015.
03.003.References
[1] E. Bokor, T. Docsa, P. Gergely, L. Somsak, Synthesis of 1-(D-
glucopyranosyl)-1,2,3-triazoles and their evaluation as glycogen
phosphorylase inhibitors, Bioorg. Med. Chem. 18 (2010) 1171–
1180.
[2] C. Gill, G. Jadhav, M. Shaikh, R. Kale, A. Ghawalkar, D.
Nagargoje, M. Shiradkar, Clubbed [1,2,3] triazoles by ﬂuorine
benzimidazole: a novel approach to H37Rv inhibitors as a
potential treatment for tuberculosis, Bioorg. Med. Chem. Lett.
18 (2008) 6244–6247.
[3] R.P. Tripathi, A.K. Yadav, A. Arya, S.S. Bisht, V. Chaturvedi,
S.K. Sinha, Application of Huisgen (3+2) cycloaddition
reaction: synthesis of 1-(2,3-dihydrobenzofuran-2-yl-methyl
[1,2,3]-triazoles and their antitubercular evaluations, Eur. J.
Med. Chem. 45 (2010) 142–148.
[4] S. Syed, M.M. Alam, N. Mulakayala, C. Mulakayala, G.
Vanaja, A.M. Kalle, R. Reddanna Pallu, M.S. Alam, Synthesis
of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-
heterocycles: their anti-inﬂammatory and anti-nociceptive
activities, Eur. J. Med. Chem. 49 (2012) 324–333.
[5] N.G. Aher, V.S. Pore, N.N. Mishra, A. Kumar, P.K. Shukla, A.
Sharma, M.K. Bhat, Synthesis and antifungal activity of 1,2,3-
triazole containing ﬂuconazole analogues, Bioorg. Med. Chem.
Lett. 19 (2009) 759–763.
[6] J.N. Sangshetti, R.R. Nagawade, D.B. Shinde, Synthesis of
novel 3-(1-(1-substituted piperidin-4-yl)-1H-1,2,3-triazol-4-yl)-
1,2,4-oxadiazol-5(4H)-one as antifungal agents, Bioorg. Med.
Chem. Lett. 19 (2009) 3564–3567.
[7] J.N. Sangshetti, A.R. Chabukswar, D.B. Shinde, One pot
synthesis and SAR of some novel 3-substituted 5,6-diphenyl-
1,2,4-triazines as antifungal agents, Bioorg. Med. Chem. Lett. 20
(2010) 742–745.
[8] L. Zhou, A. Adel, M. Korn, R. Burda, J. Balzarini, E. Clercq,
E.R. Kern, P.F. Torrence, Synthesis and antiviral activities of
1,2,3-triazole functionalized thymidines: 1,3-dipolar
cycloaddition for efﬁcient regioselective diversity generation,
Antiviral Chem. Chemother. 16 (2005) 375–383.
[9] A.Sh. El-Etrawy, A.A.-H. Abdel-Rahaman, Synthesis and
antiviral evaluation of 1,3-dimethyl-6-(1H–1,2,3-triazol-1-
yl)pyrimidine-2,4(1H,3H)-dione derivatives, Chem. Heterocycl.
Compd. 46 (2010) 1105–1108.
[10] B.S. Holla, M. Mahalinga, M.S. Karthikeyan, B. Poojary, P.M.
Akberali, N.S. Suchetha Kumari, Synthesis, characterization
and antimicrobial activity of some substituted 1,2,3-triazoles,
Eur. J. Med. Chem. 40 (2005) 1173–1178.
[11] K.D. Thomas, A.V. Adhikari, N.S. Shetty, Design, synthesis
and antimicrobial activities of some new quinoline derivatives
carrying 1,2,3-triazole moiety, Eur. J. Med. Chem. 45 (2010)
3803–3810.
[12] E. Perucca, J. Cloyd, D. Critchley, E. Fuseau, Ruﬁnamide:
clinical pharmacokinetics and concentration–response
relationships in patients with epilepsy, Epilepsia 49 (2008)
1123–1141.
[13] L. Morera, G. Labar, G. Ortar, D.M. Lambert, Development
and characterization of endocannabinoid hydrolases FAAH and
MAGL inhibitors bearing a benzotriazol-1-yl carboxamide
scaffold, Bioorg. Med. Chem. 20 (2012) 6260–6275.
[14] J.D. Venable, H. Cai, W. Chai, C.A. Dvorak, C.A. Grice, J.A.
Jablonowski, C.R. Shah, A.K. Kwok, K.S. Ly, B. Pio, J. Wei,P.J. Desai, W. Jiang, S. Nguyen, P. Ling, S.J. Wilson, P.J.
Dunford, R.L. Thurmond, T.W. Lovenberg, L. Karlsson, N.I.
Carruthers, J.P. Edwards, Preparation and biological evaluation
of indole, benzimidazole, and thienopyrrole piperazine
carboxamides: potent human histamine H4 antagonists, J.
Med. Chem. 28 (2005) 8289–8298.
[15] C.G. Oliva, N. Jagerovic, P. Goya, I. Alkorta, J. Elguero, R.
Cuberes, A. Dordal, N-substituted-1,2,3-triazoles: synthesis,
characterization and evaluation as cannabinoid ligands,
ARKIVOC 2 (2010) 127–147.
[16] Y.C. Duan, Y.C. Ma, E. Zhang, X.J. Shi, M.M. Wang, X.W.
Ye, H.M. Liu, Design and synthesis of novel 1,2,3-triazole-
dithiocarbamate hybrids as potential anticancer agents, Eur. J.
Med. Chem. 62 (2013) 11–19.
[17] Y.C. Duan, Y.C. Zheng, X.C. Li, M.M. Wang, X.W. Ye, Y.Y.
Guan, G.Z. Liu, X.J. Zhang, H.M. Liu, Design, synthesis and
antiproliferative activity studies of novel 1,2,3-triazole-
thiocarbamate-urea hybrids, Eur. J. Med. Chem. 64 (2013) 99–
110.
[18] M.S. Karthikeyan, D.J. Prasad, M. Mahalinga, B.S. Holla, N.S.
Kumari, Antimicrobial studies of 2,4-dichloro-5-ﬂuorophenyl
containing oxadiazoles, Eur. J. Med. Chem. 43 (2008) 25–31.
[19] N.P. Rai, V.K. Narayanaswamy, S. Shashikanth, P.N.
Arunachalan, Synthesis, characterization and antibacterial
activity of 2-[1-(5-chloro-2-methoxy-phenyl)-5-methyl-1H-
pyrazol-4-yl]-5-(substituted-phenyl)-[1,3,4]oxadiazoles, Eur. J.
Med. Chem. 44 (2009) 4522–4527.
[20] M.A. Bakht, M. Shahar Yar, S.G. Abdel-Hamida, S. Al
Qasoumi, A. Samada, Molecular properties prediction,
synthesis and antimicrobial activity of some newer oxadiazole
derivatives, Eur. J. Med. Chem. 45 (2010) 5862–5869.
[21] B. Chandrakantha, P. Shetty, V. Nambiar, N. Isloor, A.M.
Isloor, Synthesis, characterization and biological activity of
some new 1,3,4-oxadiazole bearing 2-ﬂouro-4-methoxy phenyl
moiety, Eur. J. Med. Chem. 45 (2010) 1206–1210.
[22] J.N. Sangshetti, A.R. Chabukswar, D.B. Shinde, Microwave
assisted one pot synthesis of some novel 2,5-disubstituted 1,3,4-
oxadiazoles as antifungal agents, Bioorg. Med. Chem. Lett. 21
(2011) 444–448.
[23] W.A. El-Sayed, O.M. Ali, H.A. Hendy, A.A-H. Abdel-Rahman,
Synthesis and antimicrobial activity of new 2,5-disubstituted
1,3,4-oxadiazoles and 1,2,4-triazoles and their sugar derivatives,
Chin. J. Chem. 30 (2012) 77–83.
[24] M. Akhter, A. Husain, B. Azad, M. Ajmal, Aroylpropionic acid
based 2,5-disubstituted-1,3,4-oxadiazoles: synthesis and their
anti-inﬂammatory and analgesic activities, Eur. J. Med. Chem.
44 (2009) 2372–2378.
[25] S.J. Gilani, S.A. Khan, N. Siddiqui, Synthesis and
pharmacological evaluation of condensed heterocyclic 6-
substituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole and 1,3,4-
oxadiazole derivatives of isoniazid, Bioorg. Med. Chem. Lett.
20 (2010) 4762–4765.
[26] G. Navarrete-Va´zquez, G.M. Molina-Salinas, Z.V. Duarte-
Fajardo, J. Vargas-Villarreal, S. Estrada-Soto, F. Gonza´lez-
Salazar, E. Herna´ndez-Nu´n˜ez, S. Said-Ferna´ndez, Synthesis and
antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-
yl)pyridines, Bioorg. Med. Chem. 15 (2007) 5502–5508.
[27] S.D. Joshi, H.M. Vagdevi, V.P. Vaidya, G.S. Gadaginamath,
Synthesis of new 4-pyrrol-1-yl benzoic acid hydrazide
analogs and some derived oxadiazole, triazole and pyrrole
ring systems: a novel class of potential antibacterial and
antitubercular agents, Eur. J. Med. Chem. 43 (2008) 1989–
1996.
[28] G.V. Suresh Kumar, Y. Rajendraprasad, B.P. Mallikarjuna,
S.M. Chandrashekar, C. Kistayya, Synthesis of some novel 2-
substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and
1,3,4-oxadiazoles as potential antimicrobial and antitubercular
agents, Eur. J. Med. Chem. 45 (2010) 2063–2074.
Evaluation of 1,4-disubstituted 1,2,3-triazole derivatives as antimicrobial agents 159[29] A. Almasirad, S.A. Tabatabai, M. Faizi, A. Kebriaeezadeh, N.
Mehrabi, A. Dalvandia, A. Shaﬁeea, Synthesis and
anticonvulsant activity of new 2-substituted-5-[2-(2-
ﬂuorophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles,
Bioorg. Med. Chem. Lett. 14 (2004) 6057–6059.
[30] M. Toth, S. Kun, E. Bokor, M. Benltifa, G. Tallec, S. Vidal, T.
Docsa, P. Gergely, L. Somsak, J.P. Praly, Synthesis and
structure–activity relationships of C-glycosylated oxadiazoles
as inhibitors of glycogen phosphorylase, Bioorg. Med. Chem. 17
(2009) 4773–4785.
[31] X.M. Zhang, M. Qiu, J. Sun, Y.B. Zhang, Y.S. Yang, X.L.
Wang, J.F. Tang, H.L. Zhu, Synthesis, biological evaluation,and molecular docking studies of 1,3,4-oxadiazole derivatives
possessing 1,4-benzodioxan moiety as potential anticancer
agents, Bioorg. Med. Chem. 19 (2011) 6518–6524.
[32] N.D. Gaikwad, S.V. Patil, V.D. Bobade, Hybrids of
ravuconazole: synthesis and biological evaluation, Eur. J.
Med. Chem. 54 (2012) 295–302.
[33] N.D. Gaikwad, S.V. Patil, V.D. Bobade, Synthesis and
biological evaluation of some novel thiazole substituted
benzotriazole derivatives, Bioorg. Med. Chem. Lett. 22 (2012)
3449–3454.
[34] E. Attolino, L. Colombo, I. Mormino, P. Allegrini, Method for
the preparation of ruﬁnamide, 2010, US2010/0234616A1.
